Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Lymphoedema Diagnostics Market: By Technology, By Disease Type, By End User and Region Forecast 2020-2031
Lymphoedema Diagnostics Market size was valued at US$ 49.5 million in 2024 and is expected to reach US$ 86.5 million by 2031, growing at a significant CAGR of 8.3% from 2025-2031. The market refers to the specialized medical segment focused on diagnosing lymphoedema; a chronic condition characterized by abnormal swelling due to the accumulation of lymphatic fluid. This market encompasses various diagnostic tools and imaging technologies, such as lymphoscintigraphy, bioimpedance spectroscopy, ultrasound, and MRI, which help detect lymphatic dysfunction and assess disease progression. The growing prevalence of lymphoedema, often linked to cancer treatments, surgeries, and genetic disorders, has driven the demand for advanced diagnostic methods. Additionally, increasing awareness among healthcare professionals and patients regarding early detection and management of lymphoedema is contributing to market growth.
The market is experiencing expansion due to the rising incidence of cancer-related lymphoedema, which affects a significant number of post-mastectomy and radiation therapy patients. Technological advancements, including non-invasive imaging techniques and portable diagnostic devices, are further enhancing the efficiency and accuracy of lymphoedema detection. Additionally, government initiatives, reimbursement policies, and research funding aimed at improving lymphatic disease diagnostics are supporting market development. North America and Europe are leading in market growth due to well-established healthcare infrastructure, while emerging economies in Asia-Pacific are witnessing increased adoption of lymphoedema diagnostic technologies due to improving medical facilities and growing patient awareness.
Based on the technology:
Near-Infrared Fluorescence (NIRF) Imaging is emerging as the leading technology in the market, driven by its high precision, non-invasive nature, and real-time imaging capabilities. This technique has gained significant traction as it enables early detection of lymphatic dysfunction with minimal patient discomfort. Compared to conventional imaging methods such as lymphoscintigraphy or MRI, NIRF imaging offers superior visualization of the lymphatic system in motion, allowing for dynamic assessments rather than static snapshots. Additionally, it eliminates the need for radioactive tracers, making it a safer and more accessible option for both patients and healthcare professionals. The increasing adoption of NIRF imaging is fueled by its growing clinical applications, particularly in cancer-related lymphoedema cases. With a rising global burden of breast cancer, cervical cancer, and melanoma, there is an urgent need for highly efficient diagnostic tools that facilitate early intervention and personalized treatment planning. Furthermore, advancements in fluorescent contrast agents and portable imaging devices are enhancing the efficiency and affordability of this technology. As a result, NIRF imaging is expected to dominate the market, driven by technological innovation, increased healthcare investments, and a shift toward minimally invasive diagnostic solutions.
Based on the disease:
Cancer is the leading disease segment in the market, primarily driven by the high prevalence of cancer-related lymphoedema and the increasing need for early detection. Cancer treatments such as surgery, radiation therapy, and chemotherapy often damage the lymphatic system, leading to fluid retention and swelling, commonly seen in breast cancer, melanoma, cervical cancer, and prostate cancer patients. As cancer incidence continues to rise globally, the demand for advanced diagnostic techniques to detect lymphatic dysfunction early and prevent severe complications has increased significantly. The growing adoption of lymphoscintigraphy, near-infrared fluorescence imaging (NIRF), and MRI in oncology settings is further accelerating the dominance of this segment. Healthcare providers are increasingly prioritizing early intervention and personalized treatment plans, making highly accurate lymphoedema diagnostics a critical part of cancer patient management. Additionally, research initiatives and government funding aimed at improving cancer-related lymphoedema diagnostics are driving technological advancements, making these solutions more accessible and efficient. With continuous innovations in imaging technology and an increasing number of cancer survivors requiring long-term lymphatic monitoring, the cancer segment is expected to maintain its leadership position in the market for the foreseeable future.
Based on the end-user:
Hospitals are the leading end-user segment in the market, driven by their advanced healthcare infrastructure, access to high-end imaging technologies, and the rising number of lymphoedema cases linked to cancer treatments and surgeries. As primary healthcare providers, hospitals play a crucial role in early diagnosis, treatment, and long-term management of lymphoedema, making them the preferred choice for patients requiring specialized diagnostic procedures. The increasing prevalence of cancer-related lymphoedema, cardiovascular diseases, and inflammatory disorders has led to a growing demand for precise and non-invasive imaging techniques such as lymphoscintigraphy, near-infrared fluorescence imaging (NIRF), and MRI, all of which are predominantly available in hospital settings. Additionally, hospitals benefit from government initiatives and funding aimed at improving diagnostic capabilities, particularly in developed regions. Multidisciplinary care teams, including oncologists, radiologists, and vascular specialists, work within hospitals to provide comprehensive lymphatic assessments, further strengthening their market dominance. The growing adoption of artificial intelligence (AI)-driven imaging solutions and portable diagnostic devices is also enhancing hospitals' ability to deliver rapid and accurate diagnostics. With continuous technological advancements and the expansion of hospital-based diagnostic services, this segment is expected to maintain its leading position in the market.
Study Period
2025-2031Base Year
2025CAGR
8.3%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
The increasing prevalence of cancer-related lymphoedema is a significant driver of the lymphoedema diagnostics industry. Cancer therapies such as mastectomy, lymph node dissection, and radiation therapy frequently cause lymphatic system damage, resulting in fluid collection and swelling in affected extremities. Breast cancer survivors, in particular, are at significant risk of developing secondary lymphoedema; studies estimate that up to 30% of breast cancer patients exhibit lymphatic malfunction after treatment. As the worldwide cancer burden grows, particularly among ageing populations, the number of lymphoedema patients is predicted to climb, demanding better diagnostic solutions. Healthcare providers and research institutions are emphasizing early detection, as timely intervention can prevent disease progression and improve patient outcomes. This has led to the increased adoption of imaging modalities such as lymphoscintigraphy, MRI, and bioimpedance spectroscopy, which provide detailed assessments of lymphatic fluid accumulation. Additionally, growing awareness programs and support groups for cancer survivors are encouraging routine lymphoedema screening, further driving the demand for diagnostic tools. The expanding application of these diagnostic techniques in cancer rehabilitation programs underscores their significance in managing post-cancer complications effectively.
Despite the potential for expansion in the market, the high cost of modern diagnostic imaging remains a significant hurdle. Technologies including MRI, lymphoscintigraphy, and near-infrared fluorescence imaging have high equipment and maintenance expenses, making them less accessible in low-income and developing countries. Furthermore, healthcare facilities frequently require specialised personnel to operate these imaging devices, which adds to operating costs. Many patients, particularly in countries with limited insurance coverage, may be unable to pay these costly diagnostic procedures, resulting in delayed or missed diagnosis. In some regions, a lack of reimbursement policies further restricts access to essential diagnostic tools, as healthcare providers may be hesitant to invest in expensive imaging equipment without financial support. Additionally, infrastructural challenges, such as inadequate radiology facilities and limited availability of trained professionals, further hinder market growth in emerging economies. To address these challenges, stakeholders in the market are focusing on cost-effective solutions, including the development of portable and AI-integrated diagnostic devices that can provide affordable and efficient detection. Nonetheless, overcoming the cost barrier remains crucial to ensuring widespread accessibility and adoption of advanced lymphoedema diagnostic technologies.
The growing emphasis on healthcare infrastructure development and government-backed initiatives to improve diagnostic accessibility represents a potential growth opportunity for the market. Many countries are investing in extending healthcare facilities, notably in the management of chronic diseases such as lymphatic illnesses. Governments and non-profit organisations are conducting awareness campaigns, financing research into better diagnostic techniques, and facilitating reimbursement rules for diagnostic treatments. For example, in the United States, the Centres for Medicare and Medicaid Services (CMS) have expanded coverage for several lymphoedema diagnostic tests, making them more accessible to patients. Similarly, in Europe, the introduction of national cancer plans that emphasize post-treatment lymphoedema management is expected to boost the demand for advanced diagnostic tools. Emerging economies in Asia-Pacific and Latin America are also witnessing increased investment in healthcare technology, driven by rising medical tourism and growing middle-class populations. The expansion of telemedicine and remote diagnostic capabilities further enhances the accessibility of lymphoedema diagnostics, enabling early detection and timely treatment even in rural and underserved areas. With continued government support and rising healthcare budgets, the market is poised for substantial expansion in the coming years.
One of the most significant trends in the lymphoedema diagnostics industry is the adoption of non-invasive and extremely precise imaging techniques. Traditional procedures, such as lymphangiography, required the injection of contrast chemicals, which increased the risk of allergic responses and patient discomfort. However, recent advances in non-invasive diagnostic techniques, such as near-infrared fluorescence imaging (NIRF) and bioimpedance spectroscopy, have revolutionised lymphoedema detection and monitoring. These technologies provide real-time visualisation of lymphatic flow without the use of contrast chemicals, which improves patient safety and diagnostic accuracy. The incorporation of artificial intelligence (AI) and machine learning into imaging technologies has improved early disease detection by enabling automated analysis of lymphatic dysfunction with minimal human error. Additionally, portable and wearable diagnostic devices are gaining traction, enabling remote monitoring of lymphoedema progression and facilitating early intervention. As healthcare systems worldwide focus on improving patient comfort and reducing hospital visits, the demand for non-invasive, AI-driven diagnostic solutions is expected to grow significantly. This trend not only enhances diagnostic capabilities but also aligns with the broader healthcare movement toward precision medicine and personalized treatment approaches.
Report Benchmarks |
Details |
Report Study Period |
2025-2031 |
Market Size in 2024 |
US$ 49.5 million |
Market Size in 2031 |
US$ 86.5 million |
Market CAGR |
8.3% |
By Technology |
|
By Disease |
|
By End User |
|
By Region |
|
PBI Analysts anticipate that the market is witnessing significant growth, driven by the rising prevalence of lymphoedema associated with cancer, cardiovascular diseases, and inflammatory disorders. The increasing number of oncology-related surgeries, particularly breast cancer procedures, has led to a surge in lymphoedema cases, necessitating advanced diagnostic solutions. Technological advancements in imaging modalities, such as lymphoscintigraphy, near-infrared fluorescence imaging (NIRF), MRI, and ultrasound, are enhancing early detection and treatment planning. Additionally, the growing adoption of AI-powered diagnostic tools and portable imaging devices is improving diagnostic accuracy and accessibility. Governments and healthcare organizations are also focusing on early intervention strategies, further propelling market growth.
The market is experiencing robust expansion in developed regions like North America and Europe, where well-established healthcare infrastructure, high awareness, and favorable reimbursement policies support diagnostic advancements. Meanwhile, emerging economies in Asia-Pacific are expected to witness rapid growth due to increasing healthcare investments, rising patient awareness, and expanding diagnostic capabilities. Despite its strong growth trajectory, the market faces challenges such as high costs of advanced imaging techniques and limited accessibility in rural areas. However, with continuous technological innovations and increasing integration of AI in diagnostics, the market is poised for sustained growth in the coming years.
Download Free Sample Report
The lymphoedema diagnostics market was valued at US$ 49.5 million in 2024 and is projected to reach US$ 86.5 million by 2031 at a CAGR of 8.3%.
One of the key drivers of the lymphoedema diagnostics market is the rising prevalence of cancer-related lymphoedema, particularly among breast cancer survivors. As the number of cancer cases continues to grow, the demand for early detection and advanced imaging technologies such as MRI, near-infrared fluorescence imaging (NIRF), and ultrasound has significantly increased, leading to market expansion.
A major trend shaping the lymphoedema diagnostics market is the integration of artificial intelligence (AI) in diagnostic imaging. AI-powered imaging tools are enhancing the accuracy, speed, and efficiency of lymphoedema detection, enabling personalized treatment plans and minimizing the risk of disease progression through early intervention.
1.Executive Summary |
2.Global Lymphoedema Diagnostics Market Introduction |
2.1.Global Lymphoedema Diagnostics Market - Taxonomy |
2.2.Global Lymphoedema Diagnostics Market - Definitions |
2.2.1.Technology |
2.2.2.Disease |
2.2.3.End User |
2.2.4.Region |
3.Global Lymphoedema Diagnostics Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Lymphoedema Diagnostics Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Lymphoedema Diagnostics Market By Technology, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
5.1. Lymphoscintigraphy |
5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Near-Infrared Fluorescence Imaging |
5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
5.3. Resonance Imaging (MRI) |
5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.3.3. Market Opportunity Analysis |
5.4. Ultrasound Imaging |
5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.4.3. Market Opportunity Analysis |
5.5. Computed Tomography (CT) |
5.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.5.3. Market Opportunity Analysis |
5.6. Others |
5.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.6.3. Market Opportunity Analysis |
6.Global Lymphoedema Diagnostics Market By Disease, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
6.1. Cancer |
6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Cardiovascular Disease |
6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Inflammatory Diseases |
6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Others |
6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
7.Global Lymphoedema Diagnostics Market By End User, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
7.1. Hospitals |
7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Diagnostic Centers |
7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Research and Academic Institutes |
7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
8.Global Lymphoedema Diagnostics Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
8.1. North America |
8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Europe |
8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Asia Pacific (APAC) |
8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
8.4. Middle East and Africa (MEA) |
8.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.4.3. Market Opportunity Analysis |
8.5. Latin America |
8.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.5.3. Market Opportunity Analysis |
9.North America Lymphoedema Diagnostics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
9.1. Technology Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.1.1.Lymphoscintigraphy |
9.1.2.Near-Infrared Fluorescence Imaging |
9.1.3.Resonance Imaging (MRI) |
9.1.4.Ultrasound Imaging |
9.1.5.Computed Tomography (CT) |
9.1.6.Others |
9.2. Disease Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.2.1.Cancer |
9.2.2.Cardiovascular Disease |
9.2.3.Inflammatory Diseases |
9.2.4.Others |
9.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.3.1.Hospitals |
9.3.2.Diagnostic Centers |
9.3.3.Research and Academic Institutes |
9.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
9.4.1.United States of America (USA) |
9.4.2.Canada |
10.Europe Lymphoedema Diagnostics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
10.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Lymphoscintigraphy |
10.1.2.Near-Infrared Fluorescence Imaging |
10.1.3.Resonance Imaging (MRI) |
10.1.4.Ultrasound Imaging |
10.1.5.Computed Tomography (CT) |
10.1.6.Others |
10.2. Disease Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Cancer |
10.2.2.Cardiovascular Disease |
10.2.3.Inflammatory Diseases |
10.2.4.Others |
10.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Hospitals |
10.3.2.Diagnostic Centers |
10.3.3.Research and Academic Institutes |
10.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Germany |
10.4.2.France |
10.4.3.Italy |
10.4.4.United Kingdom (UK) |
10.4.5.Spain |
11.Asia Pacific (APAC) Lymphoedema Diagnostics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
11.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Lymphoscintigraphy |
11.1.2.Near-Infrared Fluorescence Imaging |
11.1.3.Resonance Imaging (MRI) |
11.1.4.Ultrasound Imaging |
11.1.5.Computed Tomography (CT) |
11.1.6.Others |
11.2. Disease Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Cancer |
11.2.2.Cardiovascular Disease |
11.2.3.Inflammatory Diseases |
11.2.4.Others |
11.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Hospitals |
11.3.2.Diagnostic Centers |
11.3.3.Research and Academic Institutes |
11.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.China |
11.4.2.India |
11.4.3.Australia and New Zealand (ANZ) |
11.4.4.Japan |
11.4.5.Rest of APAC |
12.Middle East and Africa (MEA) Lymphoedema Diagnostics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
12.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Lymphoscintigraphy |
12.1.2.Near-Infrared Fluorescence Imaging |
12.1.3.Resonance Imaging (MRI) |
12.1.4.Ultrasound Imaging |
12.1.5.Computed Tomography (CT) |
12.1.6.Others |
12.2. Disease Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Cancer |
12.2.2.Cardiovascular Disease |
12.2.3.Inflammatory Diseases |
12.2.4.Others |
12.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Hospitals |
12.3.2.Diagnostic Centers |
12.3.3.Research and Academic Institutes |
12.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.GCC Countries |
12.4.2.South Africa |
12.4.3.Rest of MEA |
13.Latin America Lymphoedema Diagnostics Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
13.1. Technology Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Lymphoscintigraphy |
13.1.2.Near-Infrared Fluorescence Imaging |
13.1.3.Resonance Imaging (MRI) |
13.1.4.Ultrasound Imaging |
13.1.5.Computed Tomography (CT) |
13.1.6.Others |
13.2. Disease Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Cancer |
13.2.2.Cardiovascular Disease |
13.2.3.Inflammatory Diseases |
13.2.4.Others |
13.3. End User Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Hospitals |
13.3.2.Diagnostic Centers |
13.3.3.Research and Academic Institutes |
13.4. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Brazil |
13.4.2.Mexico |
13.4.3.Rest of LA |
14. Competition Landscape |
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
14.2.1.Bausch Health Companies |
14.2.2.Galderma S.A |
14.2.3.Celtic Pharma |
14.2.4.Anacor Pharmaceuticals, Inc. |
14.2.5.Novartis AG, Pfizer Inc. |
14.2.6.GlaxoSmithKline Inc. |
14.2.7.Cipla Ltd. |
14.2.8.Merz Pharma |
14.2.9.NovaBiotics Inc. |
14.2.10.GE Healthcare |
14.2.11.United Imaging Healthcare. |
15. Research Methodology |
16. Appendix and Abbreviations |
Key Market Players